ecrin-mdr-crcClinical2003Colorectal Cancer (CRC)Metastatic Colorectal Cancer resistant to or unsuitable for treatment with 5-fluorouracil and irinotecan and/or oxaliplatinColorectal NeoplasmsColorectal Cancer (crc)Metastatic Colorectal Cancer Resistant To Or Unsuitable For Treatment With 5-fluorouracil And Irinotecan And/or OxaliplatinColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2016943NetherlandsFranceGermany3indisulamXeloda 150 mg film-coated tabletsN-(3-chloro-7-indolyl)-1,4-benzenedisulphonamideXeloda 500 mg film-coated tabletsECRIN MDRCompletedfalseStudy of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal CancerPart 1: The primary purpose is to determine the recommended dose of E7070 in combination with capecitabine by dose adjustment. Part 2: The primary purpose is to determine the safety and efficacy of the combination in patients with metastatic CRC resistant to 5-fluorouracil and irinotecan.2003-03-152016943NCT001658542004-002597-33